Huaren Pharmaceutical (300110.SZ) has dismissed Hong Liang from the position of CEO.
Huarun Pharmaceutical (300110.SZ) announced that the company will hold the eighth session of the board of directors on December 27, 2024.
Huaren Pharmaceutical (300110.SZ) issued an announcement, stating that on December 27, 2024, the company held the sixth (interim) meeting of the eighth board of directors, where they approved the motion for the dismissal of the company's CEO. According to the company's needs for operational management, and after review by the board of directors' nomination committee, the board of directors agreed to dismiss Mr. Hong Liang from his position as CEO, with the dismissal taking effect from the date of the board meeting. After the dismissal, Mr. Hong Liang will no longer hold any position within the company, and this dismissal will not have any adverse effects on the company's normal operational activities.
Related Articles
Shenzhen Hello Tech Energy(301327.SZ): Strong performance hits record high, revenue and net profit both break through.
Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.
HK Bull/Bear Outstanding Qty Ratio(52:48) | April 26th
Shenzhen Hello Tech Energy(301327.SZ): Strong performance hits record high, revenue and net profit both break through.
Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.
HK Bull/Bear Outstanding Qty Ratio(52:48) | April 26th
RECOMMEND
Pan Gongsheng: Will implement a moderately loose monetary policy to promote high-quality development of the Chinese economy.
25/04/2025
Canadian Prime Minister Trudeau: No rush to reach agreement with Trump, US side eventually needs to face reality.
25/04/2025
Alphabet (GOOG.US, GOOGL.US) first quarter revenue and profits exceed expectations, driven by AI and cloud computing performance growth.
25/04/2025
